- Home
- OABI vs ACIU Comparison
OABI vs ACIU Comparison
Compare OABI & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OABI
- ACIU
- Stock Information
- Founded
- OABI 2012
- ACIU 2003
- Country
- OABI United States
- ACIU Switzerland
- Employees
- OABI N/A
- ACIU N/A
- Industry
- OABI Biotechnology: Pharmaceutical Preparations
- ACIU Biotechnology: Pharmaceutical Preparations
- Sector
- OABI Health Care
- ACIU Health Care
- Exchange
- OABI Nasdaq
- ACIU Nasdaq
- Market Cap
- OABI 198.2M
- ACIU 168.7M
- IPO Year
- OABI N/A
- ACIU 2016
- Fundamental
- Price
- OABI $1.66
- ACIU $2.07
- Analyst Decision
- OABI Strong Buy
- ACIU Strong Buy
- Analyst Count
- OABI 3
- ACIU 1
- Target Price
- OABI $7.00
- ACIU $12.00
- AVG Volume (30 Days)
- OABI 1.1M
- ACIU 119.1K
- Earning Date
- OABI 08-07-2025
- ACIU 08-05-2025
- Dividend Yield
- OABI N/A
- ACIU N/A
- EPS Growth
- OABI N/A
- ACIU N/A
- EPS
- OABI N/A
- ACIU N/A
- Revenue
- OABI $26,744,000.00
- ACIU $32,014,254.00
- Revenue This Year
- OABI N/A
- ACIU N/A
- Revenue Next Year
- OABI $45.65
- ACIU $533.21
- P/E Ratio
- OABI N/A
- ACIU N/A
- Revenue Growth
- OABI 27.07
- ACIU 91.20
- 52 Week Low
- OABI $1.22
- ACIU $1.43
- 52 Week High
- OABI $4.96
- ACIU $4.37
- Technical
- Relative Strength Index (RSI)
- OABI 53.98
- ACIU 59.88
- Support Level
- OABI $1.55
- ACIU $1.79
- Resistance Level
- OABI $1.73
- ACIU $2.10
- Average True Range (ATR)
- OABI 0.11
- ACIU 0.17
- MACD
- OABI 0.02
- ACIU 0.00
- Stochastic Oscillator
- OABI 68.13
- ACIU 71.93
About OABI OmniAb Inc.
OmniAb Inc offers therapeutic antibody discovery technologies. It focuses on enabling the rapid development of therapeutics by pushing the frontiers of drug discovery technologies. Its technology platform is designed to enable the efficient discovery of high-quality, fully human antibodies for a wide range of diseases. The heart of the OmniAb technology platform is the Biological Intelligence of its proprietary transgenic animals, including OmniRat, OmniMouse, and OmniChicken, that have been genetically modified to generate antibodies with human sequences which are naturally optimized through in vivo affinity maturation.
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses most of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.